Inhibitors of the Influenza A Virus M2 Proton Channel Discovered Using a High-Throughput Yeast Growth Restoration Assay

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Balgi, Aruna D ^a   Wang, Jun ^b   Cheng, Daphne Y H ^a   Ma, Chunlong ^c   Pfeifer, Tom A ^d   Shimizu, Yoko ^d   Anderson, Hilary J ^a   Pinto, Lawrence H ^c   Lamb, Robert A ^c   DeGrado, William F ^b   Roberge, Michel ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Centre for Drug Research and Development   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1,7,7 TRIMETHYLBICYCLO(2.2.1)HEPT 2 YL]PIPERAZINE; 1 [BICYCLO(2.2.1)HEPTAN 2 YL]ETHAN 1 AMINIUM: PYRIDINE 3 CARBOXYLATE; 1 ADAMANTYL(4 NITROBENZYL)AMINE; 2 (METHYLAMINO) 1 TRICYCLO(4.3.1.1-3,8)UNDEC 1 YLETHANONE; 2 ADAMANTYL(1,3 BENZODIOXOL 5 YL)AMINE; 2 ADAMANTYL(2 NITROBENZYL)AMINE; 3 AMINO BETA PINENE; 3 BENZYL 6 (ETHYLTHIO) 1,2,3,4 TETRAHYDRO 1,3,5 TRIAZINE; 3 BENZYL 6 (METHYLTHIO) 1,2,3,4 TETRAHYDRO 1,3,5 TRIAZINE HYDROIODIDE; 5 (ADAMANTAN 1 YL) 2 METHYL 1H IMIDAZOLE; 5 [(1 ADAMANTYLAMINO)METHYLENE] 2 THIOXODIHYDRO 4,6(1H,5H)PYRIMIDINEDIONE; 6 (ETHYLTHIO) 3 (FURAN 2 YLMETHYL) 1,2,3,4 TETRAHYDRO 1,3,5 TRIAZINE; 6 (ETHYLTHIO) 3 (THIOPHEN 2 YLMETHYL) 1,2,3,4 TETRAHYDRO 1,3,5 TRIAZINE; 6 (ETHYLTHIO) 3 [2(THIOPHEN 2 YL)ETHYL] 1,2,3,4 TETRAHYDRO 1,3,5 TRIAZINE; 6 (METHYLTHIO) 3 (THIOPHEN 2 YLMETHYL) 1,2,3,4 TETRAHYDRO 1,3,5 TRIAZINE; [1 (ADAMANTAN 1 YLMETHYL)PYRROLIDIN 2 YL]METHANOL; AMANTADINE; ANTIVIRUS AGENT; HEXAMETHYLENE AMILORIDE; METHYL N [(3,5,7)ADAMANTAN 1YL] N CYANOCARBAMIMIDOTHIOATE; N (ADAMANTAN 1 YLMETHYL) 3 ETHYL 5 METHYL 1,2 OXAZOLE 4 CARBOXAMIDE; N (ADAMANTAN 1 YLMETHYL) 4,5 DIHYDRO 1H IMIDAZOL 2 AMINE HYDROIODIDE; N (ADAMANTAN 2 YL) 5 METHYL 1,2 OXAZOLE 3 CARBOXAMIDE; N [(1 METHYL 1H PYRROL 2 YL)METHYL]CYCLOOCTANAMINE; N [[[1 (1 ADAMANTYL)ETHYL]AMINO]CARBONOTHIOYL] 3 (2 FURYL)ACRYLAMIDE; N1 [4[(1 ADAMANTYLAMINO)SULFONYL]PHENYL]ACETAMIDE; PROTEIN M2; RIMANTADINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GROWTH INHIBITION; IC 50; INFLUENZA VIRUS A; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SACCHAROMYCES CEREVISIAE; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY; VOLTAGE CLAMP; YEAST GROWTH RESTORATION ASSAY;

ANTIVIRAL AGENTS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MUTATION, MISSENSE; PATCH-CLAMP TECHNIQUES; SENSITIVITY AND SPECIFICITY; VIRAL MATRIX PROTEINS; YEASTS;

EID: 84873272442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055271     Document Type: Article

References (55)

1. World Health Organization (2009) Influenza (Seasonal). Fact sheet No. 211, Available: http://www.who.int/mediacentre/factsheets/fs211/en/index.html. Accessed 2012 August 2.
2. Nicholls H, (2006) Pandemic Influenza: The Inside Story. PLoS Biol 4: e50.
3. World Health Organization (2009) Pandemic (H1N1) 2009- update 75, Available: http://www.who.int/csr/don/2009_11_20a/en/index.html.Accessed 2012 August 2.
4. Viboud C, Simonsen L (2012) Global mortality of 2009 pandemic influenza A H1N1. The Lancet Infectious Diseases doi:10.1016/S1473-3099(12)70152-4.
5. Das K (2012) Antivirals Targeting Influenza A Virus. J Med Chem ASAP.
6. Bright RA, Medina M-j, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. The Lancet 366: 1175-1181.
7. Bright Ra SDKSBCNJKAI, (2006) ADamantane resistance among influenza a viruses isolated early during the 2005-2006 influenza season in the united states. JAMA: The Journal of the American Medical Association 295: 891-894.
8. Hayden FG, de Jong MD, (2011) Emerging Influenza Antiviral Resistance Threats. J Infect Dis 203: 6-10.
9. Moore C, Galiano M, Lackenby A, Abdelrahman T, Barnes R, et al. (2011) Evidence of Person-to-Person Transmission of Oseltamivir-Resistant Pandemic Influenza A(H1N1) 2009 Virus in a Hematology Unit. J Infect Dis 203: 18-24.
10. Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, et al. (2011) Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008-2010. J Infect Dis 203: 13-17.
11. Govorkova EA, McCullers JA (2012) Therapeutics against influenza. Curr Top Microbiol Immunol Epub ahead of print.
12. Duque MD, Valverde E, Barniol M, Guardiola S, Rey M, et al. (2011) Inhibitors of the M2 channel of influenza A virus. Recent Advances in Pharmaceutical Sciences: 35-64.
13. Helenius A, (1992) Unpacking the incoming influenza virus. Cell 69: 577-578.
14. Grambas S, Hay AJ, (1992) Maturation of influenza A virus hemagglutinin-estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 190: 11-18.
15. Sakaguchi T, Leser GP, Lamb RA, (1996) The ion channel activity of the influenza virus M(2) protein affects transport through the Golgi apparatus. J Cell Biol 133: 733-747.
16. Martin K, Heleniust A, (1991) Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import. Cell 67: 117-130.
17. Wang J, Qiu JX, Soto C, DeGrado WF, (2011) Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Strcut Biol 21: 68-80.
18. Grambas S, Bennett MS, Hay AJ, (1992) Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 191: 541-549.
19. Furuse Y, Suzuki A, Kamigaki T, Oshitani H (2009) Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol J 6.
20. Furuse Y, Suzuki A, Oshitani H, (2009) Large-Scale Sequence Analysis of M Gene of Influenza A Viruses from Different Species: Mechanisms for Emergence and Spread of Amantadine Resistance. Antimicrob Agents Chemother 53: 4457-4463.
21. Giffin K, Rader RK, Marino MH, Forgey RW, (1995) Novel assay for the influenza virus M2 channel activity. FEBS Lett 357: 269-274.
22. Balannik V, Obrdlik P, Inayat S, Steensen C, Wang J, et al. (2010) Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity. Pflug Arch Eur J Phy 459: 593-605.
23. Leiding T, Wang J, Martinsson J, DeGrado WF, Arskold SP, (2010) Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc Natl Acad Sci U S A 107: 15409-15414.
24. Kurtz S, Luo GX, Hahnenberger KM, Brooks C, Gecha O, et al. (1995) Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Antimicrob Agents Chemother 39: 2204-2209.
25. Astrahan P, Flitman-Tene R, Bennett ER, Krugliak M, Gilon C, et al. (2011) Quantitative analysis of influenza M2 channel blockers. Biochim Biophys Acta (BBA)-Biomembranes 1808: 394-398.
26. Wang J, Ma C, Fiorin G, Carnevale V, Wang T, et al. (2011) Molecular Dynamics Simulation Directed Rational Design of Inhibitors Targeting Drug-Resistant Mutants of Influenza A Virus M2. J Am Chem Soc 133: 12834-12841.
27. Balannik V, Wang J, Ohigashi Y, Jing XH, Magavern E, et al. (2009) Design and Pharmacological Characterization of Inhibitors of Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A Virus. Biochemistry 48: 11872-11882.
28. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479.
29. Quinn RJ, Carroll AR, Pham NB, Baron P, Palframan ME, et al. (2008) Developing a Drug-like Natural Product Library. J Nat Prod 71: 464-468.
30. Wang J, Ma C, Balannik V, Pinto LH, Lamb RA, et al. (2011) Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in Inhibitors of M2 from Influenza A Virus. ACS Med Chem Lett 2: 307-312.
31. Zhao X, Li C, Zeng S, Hu W, (2011) Discovery of highly potent agents against influenza A virus. Eur J Med Chem 46: 52-57.
32. Hu W, Zeng S, Li C, Jie Y, Li Z, et al. (2010) Identification of Hits as Matrix-2 Protein Inhibitors through the Focused Screening of a Small Primary Amine Library. J Med Chem 53: 3831-3834.
33. Acharya R, Carnevale V, Fiorin G, Levine BG, Polishchuk AL, et al. (2010) Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc Natl Acad Sci U S A 107: 15075-15080.
34. Wang J, Cady SD, Balannik V, Pinto LH, DeGrado WF, et al. (2009) Discovery of Spiro-Piperidine Inhibitors and Their Modulation of the Dynamics of the M2 Proton Channel from Influenza A Virus. J Am Chem Soc 131: 8066-8076.
35. Garcia Martinez A, Teso Vilar E, Garcia Fraile A, De La Moya Cerero S, Rodriguez Herrero ME, et al. (1995) Synthesis of substituted 1-norbornylamines with antiviral activity. J Med Chem 38: 4474-4477.
36. Lin TI, Heider H, Schroeder C, (1997) Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein. J Gen Virol 78: 767-774.
37. Eleftheratos S, Spearpoint P, Ortore G, Kolocouris A, Martinelli A, et al. (2010) Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-Docking using a pore blocking model. Bioorg Med Chem Lett 20: 4182-4187.
38. Fiorin G, Carnevale V, DeGrado WF, (2010) The Flu's Proton Escort. Science 330: 456-458.
39. Hu F, Luo W, Hong M, (2010) Mechanisms of Proton Conduction and Gating in Influenza M2 Proton Channels from Solid-State NMR. Science 330: 505-508.
40. Sharma M, Yi M, Dong H, Qin H, Peterson E, et al. (2010) Insight into the Mechanism of the Influenza A Proton Channel from a Structure in a Lipid Bilayer. Science 330: 509-512.
41. Cady SD, Schmidt-Rohr K, Wang J, Soto CS, DeGrado WF, et al. (2010) Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463: 689-692.
42. Schnell JR, Chou JJ, (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-U512.
43. Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, et al. (2008) Structural basis for the function and inhibition of an influenza virus proton channel Nature. 452: 380-380.
44. Cady SD, Wang J, Wu Y, DeGrado WF, Hong M, (2011) Specific Binding of Adamantane Drugs and Direction of Their Polar Amines in the Pore of the Influenza M2 Transmembrane Domain in Lipid Bilayers and Dodecylphosphocholine Micelles Determined by NMR Spectroscopy. J Am Chem Soc 133: 4274-4284.
45. Balgi AD, Roberge M, (2009) Screening for chemical inhibitors of heterologous proteins expressed in yeast using a simple growth-restoration assay. Methods Mol Biol 486: 125-137.
46. Vottero E, Balgi A, Woods K, Tugendreich S, Melese T, et al. (2006) Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast. Biotechnol J 1: 282-288.
47. Camp D, Davis RA, Campitelli M, Ebdon J, Quinn RJ, (2012) Drug-like Properties: Guiding Principles for the Design of Natural Product Libraries. J Nat Prod 75: 72-81.
48. Kleyman TR, Cragoe EJ, (1988) Amiloride and its analogs as tools in the study of ion transport. J Membr Biol 105: 1-21.
49. Ewart GD, Mills K, Cox GB, Gage PW, (2002) Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J 31: 26-35.
50. Premkumar A, Wilson L, Ewart GD, Gage PW, (2004) Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett 557: 99-103.
51. Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang FL, et al. (2009) Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel. PLoS Pathog 5: e1000511.
52. Simchowitz L, Cragoe EJ, (1986) Inhibition of chemotactic factor-activated Na+/H+ exchange in human neutrophils by analogues of amiloride: structure-activity relationships in the amiloride series. Mol Pharmacol 30: 112-120.
53. Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, et al. (2010) Antiviral properties, metabolism, and pharmacokinetics of a novel lead azolo-1,2,4-triazine-derived inhibitor of influenza A and B replication. Antimicrob Agents Chemother 54: 2017-2022.
54. Pathania R, Zlitni S, Barker C, Das R, Gerritsma DA, et al. (2009) Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol 5: 849-856.
55. Curman D, Cinel B, Williams DE, Rundle N, Block WD, et al. (2001) Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 276: 17914-17919.